Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,113.50    -11.50 (-1.02%)
Bid:
1,116.00
Ask:
1,116.50
Spread: 0.50 (0.045%)
Market Cap: £9.42b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Director/PDMR Shareholding

21 May 2025 15:00

RNS Number : 6489J
Smith & Nephew Plc
21 May 2025
 

SMITH & NEPHEW PLC

 

21 May 2025

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

 

1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020

 

On 20 May 2025, the Company received notification of the following transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.

 

All figures in these columns are stated to 6 decimal places where applicable.

 

i. VESTING OF PERFORMANCE SHARE PLAN AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

 

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025 at 59.35% of target. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below. The number of Shares acquired includes the dividend equivalent Shares which the participant received on the vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Vesting on 20 May 2025 of Performance Share Plan awards granted under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

2025 - 05 - 20

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Deepak Nath

(Chief Executive Officer)

PDMR

10.875359

83,938 (of which 34,477 were sold and 49,461 were retained)

N/A Single Transaction

 

 

ii. VESTING OF CONDITIONAL AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

 

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Vesting on 20 May 2025 of Conditional Share awards granted under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

2025 - 05 - 20

Place of Transaction

London Stock Exchange (XLON)

 

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Craig Gaffin

(President, Global Orthopaedics)

PDMR

10.875359

 

1,551 (of which 379 were sold and 1,172 were retained)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

10.875359

20,174 (of which 8,026 were sold and 12,148 were retained)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development and ENT)

PDMR

10.875359

19,626 (of which 8,708 were sold and 10,918 were retained)

N/A Single Transaction

Rohit Kashyap

(President, Advanced Wound Management and Global Commercial Operations)

PDMR

10.875359

11,949 (of which 2,920 were sold and 9,029 retained)

N/A Single Transaction

 

 

 

Philip Horner

Deputy Company Secretary

Smith & Nephew plc

 

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFSVETILFIE
Date   Source Headline
1st Aug 20172:02 pmRNSBlock listing Interim Review
1st Aug 20171:54 pmRNSBlock Listing Cancellation
1st Aug 20171:26 pmRNSTotal Voting Rights
1st Aug 20179:54 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSHalf-year Report
13th Jul 201711:42 amRNSNotice of Results
12th Jul 20174:44 pmRNSDirector/PDMR Shareholding
4th Jul 20178:04 amRNSDirectorate Change
3rd Jul 201710:56 amRNSTotal Voting Rights
8th Jun 20174:11 pmRNSTransaction in Own Shares
1st Jun 20171:59 pmRNSTotal Voting Rights
23rd May 20174:22 pmRNSTransaction in Own Shares
22nd May 20175:39 pmRNSTransaction in Own Shares
19th May 20175:18 pmRNSTransaction in Own Shares
18th May 20175:25 pmRNSTransaction in Own Shares
18th May 20172:29 pmRNSDirector/PDMR Shareholding
15th May 20171:54 pmRNSTransaction in Own Shares
12th May 20172:18 pmRNSDirector/PDMR Shareholding
11th May 201710:55 amRNSDirector/PDMR Shareholding
5th May 20177:00 amRNSTrading Statement
2nd May 201712:04 pmRNSTotal Voting Rights
26th Apr 20172:05 pmRNSDividend Declaration
11th Apr 20171:04 pmRNSNotice of Results
10th Apr 20174:12 pmRNSDirector/PDMR Shareholding
6th Apr 20174:50 pmRNSResult of AGM
3rd Apr 20173:07 pmRNSTotal Voting Rights
24th Mar 20173:03 pmRNSDirector/PDMR Shareholding
23rd Mar 20171:42 pmRNSAdditional Listing
10th Mar 20174:20 pmRNSDirector/PDMR Shareholding
8th Mar 20179:17 amRNSDirector/PDMR Shareholding
6th Mar 20171:49 pmRNSAnnual Financial Report - Replacement
6th Mar 20171:04 pmRNSAnnual Financial Report
1st Mar 20171:16 pmRNSTotal Voting Rights
21st Feb 20175:44 pmRNSTransaction in Own Shares
20th Feb 20175:46 pmRNSTransaction in Own Shares - Amendment
20th Feb 20175:28 pmRNSTotal Voting Rights
16th Feb 20175:44 pmRNSTransaction in Own Shares
15th Feb 20175:23 pmRNSDirector/PDMR Shareholding
14th Feb 20175:46 pmRNSTransaction in Own Shares
13th Feb 20174:08 pmRNSDirector/PDMR Shareholding
13th Feb 20179:23 amRNSTransaction in Own Shares
9th Feb 20177:05 amRNSDirectorate Change
9th Feb 20177:00 amRNSFinal Results
1st Feb 20176:28 pmRNSBlocklisting Interim Review
1st Feb 20175:28 pmRNSTotal Voting Rights
17th Jan 20175:05 pmRNSDirector/PDMR Shareholding
12th Jan 201712:14 pmRNSDirectorate Change
3rd Jan 20174:47 pmRNSTotal Voting Rights
21st Dec 20165:01 pmRNSNotice of Results
21st Dec 20161:48 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.